| Boehringer Ingelheim announces results of Transcend trial | Posted on 01/09/2008 in Pharmaceutical Company Product News Boehringer Ingelheim has announced the results of the Transcend trial of Micardis (telmisartan), with the compound reducing the risk of heart attack, stroke and cardiovascular death in ACE-intolerant patients deemed to be at high risk.
The results were presented at the annual meeting of the European Society of Cardiology in Munich, Germany.
In the study, patients treated with Micardis 80mg showed a 13 per cent reduction in risk of cardiovascular death, myocardial infarction and stroke compared to those already receiving best standard of care.
Furthermore, a non-statistically significant eight per cent reduction of the composite of cardiovascular death, stroke, myocardial infarction and congestive heart failure hospitalisation was seen in the trial.
Professor Salim Yusuf, director of the Population Health Research Institute at McMaster University, Hamilton, Canada, said: "Earlier this year, the Ontarget trial showed that telmisartan is as protective as, but better tolerated than the ACE-inhibitor ramipril."
He added the results from the Transcend trial show moderate but vital progress for high-risk patients who are intolerant to ACE inhibitors.
In June 2008, Boehringer Ingelheim announced the results of two trials showing treatment regimens based on Micardis can help more patients attain their blood pressure goals.Other news stories from 01/09/2008
Read more in the Zenopa News Archive
How this news is generated
|  |
|
